Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis

被引：2
|
作者：
Zhao, Cathy Yunjia [1 ,2 ]
Chou, Shaun [1 ,3 ]
Liu, Rose Congwei [1 ,2 ]
Fernandez-Penas, Pablo [1 ,2 ]
机构：
[1] Westmead Hosp, Dept Dermatol, Sydney, NSW, Australia
[2] Univ Sydney, Med, Sydney, NSW, Australia
[3] Westmead Hosp, Inst Clin Pathol & Med Res, Sydney, NSW, Australia
来源：
PIGMENT CELL & MELANOMA RESEARCH | 2018年 / 31卷 / 02期
关键词：
MELANOCYTIC LESIONS;
D O I：
10.1111/pcmr.12669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
    Lai, Xiulan
    Friedman, Avner
    BMC SYSTEMS BIOLOGY, 2017, 11
  • [2] Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
    Hui, Caressa
    Wu, Yufan
    Liu, Kevin
    Sandhu, Navjot
    Blomain, Erik
    Binkley, Michael S.
    Gephart, Melanie H.
    Chang, Steven D.
    Li, Gordon H.
    Reddy, Sunil A.
    Soltys, Scott G.
    Pollom, Erqi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (11)
  • [3] Intracranial Response to Combination BRAF and MEK Inhibitor Therapy in Patients with Metastatic Melanoma
    Hui, Caressa
    Wu, Yufan
    Liu, Kevin
    Sandhu, Navjot
    Blomain, Erik
    Binkley, Michael
    Gephart, Melanie
    Chang, Steven
    Li, Gordon
    Reddy, Sunil
    Gibbs, Iris
    Soltys, Scott
    Pollom, Erqi
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : S48 - S49
  • [4] Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
    Sanlorenzo, Martina
    Choudhry, Aditi
    Vujic, Igor
    Posch, Christian
    Chong, Kim
    Johnston, Katia
    Meier, Melissa
    Osella-Abate, Simona
    Quaglino, Pietro
    Daud, Adil
    Algazi, Alain
    Rappersberger, Klemens
    Ortiz-Urda, Susana
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (06) : 1102 - U117
  • [5] The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma
    Dimitriou, Florentia
    Urner-Bloch, Ursula
    Eggenschwiler, Corinne
    Mitsakakis, Nicholas
    Mangana, Joanna
    Dummer, Reinhard
    Urner, Martin
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 215 - 223
  • [6] Targeted combination therapy of BRAF/MEK inhibitor-resistant melanoma cells
    Hamel, A.
    Kammerbauer, C.
    Graf, S. A.
    Berking, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 7 - 8
  • [7] Targeted combination therapy for BRAF/MEK inhibitor-resistant melanoma cells
    Hamel, A.
    Kammerbauer, C.
    Graf, S. A.
    Berking, C.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 (03) : E37 - E37
  • [8] Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
    Booth, Andrew E. C.
    Hopkins, Ashley M.
    Rowland, Andrew
    Kichenadasse, Ganessan
    Smith, Justine R.
    Sorich, Michael J.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [9] Successful Combination Therapy of BRAF- and MEK-Inhibitor after Progress under BRAF-Inhibitor Mono Therapy: Report of a Patient with brain metastatic Melanoma
    Asper, H.
    Satger, I
    Tolk, H.
    Kapp, A.
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 166 - 166
  • [10] Patients with stage IV melanoma with BRAF mutation - immunotherapy or BRAF and MEK inhibitors in first line therapy?
    Cybulska-Stopa, Bozena
    Ziobro, Marek
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 : A9 - A12
12345